

CITATION REPORT

List of articles citing

Curing myeloma at last: defining criteria and providing the evidence

DOI: 10.1182/blood-2014-07-552059
Blood, 2014, 124, 3043-51.

Source: <https://exaly.com/paper-pdf/59904777/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
179	Haematological cancer: Optimizing the treatment of multiple myeloma. 2014 , 11, 686-8		
178	Myeloma cell-derived Runx2 promotes myeloma progression in bone. <i>Blood</i> , 2015 , 125, 3598-608	2.2	37
177	Myeloma escape from immunity: an "inside" job. <i>Blood</i> , 2015 , 126, 1401-3	2.2	3
176	Consolidation and maintenance inde novofirst-line multiple myeloma with modern agents. 2015 , 4, 9-22		1
175	Deep Response in Multiple Myeloma: A Critical Review. 2015 , 2015, 832049		26
174	New insights into malignant B-cell disorders. 2015 , 2015, 128084		
173	Treatment of relapsed multiple myeloma. 2015 , 65-77		
172	SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma. <i>EBioMedicine</i> , 2015 , 2, 13-4	8.8	
171	High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "DeNovo" Multiple Myeloma Patients: A Phase II Study. 2015 , 21, 1932-8		16
170	Handbook of Multiple Myeloma. 2015 ,		3
169	Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. <i>Leukemia</i> , 2015 , 29, 1195-201	10.7	29
168	Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients. 2015 , 8, 22-25		0
167	New criteria for response assessment: role of minimal residual disease in multiple myeloma. <i>Blood</i> , 2015 , 125, 3059-68	2.2	205
166	The Diagnosis and Treatment of Multiple Myeloma. 2016 , 113, 470-6		73
165	Management of multiple myeloma first relapse after autologous hematopoietic stem cell transplantation. 2016 , 22, 395-405		
164	Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?. 2016 , 270, 78-94		6
163	Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. 2016 , 172, 685-98		38

162	Utility of flow cytometry studies in the management of patients with multiple myeloma. 2016 , 28, 511-517		15
161	Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. 2016 , 376, 278-83		42
160	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. <i>Blood</i> , 2016 , 127, 1896-906	2.2	65
159	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. <i>Blood</i> , 2016 , 127, 3165-74	2.2	99
158	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. <i>Blood</i> , 2016 , 128, 1735-44	2.2	129
157	Multiple Myeloma Minimal Residual Disease. 2016 , 169, 103-122		12
156	Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. <i>Blood Cancer Journal</i> , 2016 , 6, e453	7	18
155	Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus. <i>Advanced Materials</i> , 2016 , 28, 9573-9580	24	147
154	Multiple myeloma: disease response assessment. <i>Expert Review of Hematology</i> , 2016 , 9, 831-7	2.8	7
153	Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. 2016 , 96, 119-27		7
152	Oral ixazomib maintenance therapy in multiple myeloma. 2016 , 16, 21-32		5
151	Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. 2016 , 35, 3955-64		47
150	Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. 2016 , 11, 118-26		10
149	Is it possible to cure myeloma without allogeneic transplantation?. <i>Transfusion and Apheresis Science</i> , 2016 , 54, 63-70	2.4	8
148	Early Versus Delayed Autologous Stem Cell Transplantation and Interferon Maintenance in Multiple Myeloma: Single-Center Experience of 18 Years. 2016 , 48, 177-84		12
147	The safety of pomalidomide for the treatment of multiple myeloma. 2016 , 15, 535-47		5
146	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. <i>Leukemia</i> , 2017 , 31, 2094-2103	10.7	298
145	Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. 2017 , 281, 365-382		93

144	How I manage the toxicities of myeloma drugs. <i>Blood</i> , 2017 , 129, 2359-2367	2.2	28
143	Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. 2017 , 8, 165-169		8
142	End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. 2017 , 13, 1181-1193		19
141	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. 2017 , 23, 3980-3993		51
140	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. <i>Haematologica</i> , 2017 , 102, e313-e316	6.6	21
139	Recent advances in understanding multiple myeloma. 2017 , 10, 267-271		15
138	RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. 2017 , 177, 80-94		33
137	Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. <i>Blood Cancer Journal</i> , 2017 , 7, e549	7	60
136	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. 2017 , 92, 578-598		88
135	Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. 2017 , 8, 55-70		25
134	IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma. 2017 , 92, 269-278		6
133	Current applications of multiparameter flow cytometry in plasma cell disorders. <i>Blood Cancer Journal</i> , 2017 , 7, e617	7	26
132	Evolutionary biology of high-risk multiple myeloma. 2017 , 17, 543-556		119
131	Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. <i>Nature Communications</i> , 2017 , 8, 268	17.4	170
130	The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. <i>Haematologica</i> , 2017 , 102, 2113-2124	6.6	13
129	Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry. 2017 , 92, E611-E614		8
128	Standardisation of minimal residual disease in multiple myeloma. 2017 , 26, e12732		8
127	The proteasome and proteasome inhibitors in multiple myeloma. 2017 , 36, 561-584		150

126	Diagnostik und Therapie des Multiplen Myeloms. 2017 , 20, 44-52		
125	How I treat first relapse of myeloma. <i>Blood</i> , 2017 , 130, 963-973	2.2	49
124	Drug Combinations with Transplantation for Myeloma. 2017 , 377, 91-2		1
123	Living with Multiple Myeloma: A Continuum-Based Approach to Cancer Survivorship. 2017 , 33, 348-361		12
122	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. 2017 , 23, 2665-2672		9
121	Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. <i>Leukemia</i> , 2017 , 31, 637-644.7		20
120	Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. 2017 , 52, 41-47		11
119	Integration of Genomics Into Treatment: Are We There Yet?. 2017 , 37, 569-574		1
118	Is molecular remission the goal of multiple myeloma therapy?. <i>Hematology American Society of Hematology Education Program</i> , 2017 , 2017, 205-211	3.1	13
117	Update on the optimal use of bortezomib in the treatment of multiple myeloma. 2017 , 9, 51-63		34
116	Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. 2017 , 11, 2399-2408		23
115	VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma. 2017 , 10, 217-226		5
114	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. 2017 , 35, 2900-2910		175
113	Proteasome inhibitors for the treatment of multiple myeloma. 2018 , 19, 375-386		21
112	Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. <i>Annals of Hematology</i> , 2018 , 97, 925-944	3	21
111	Treatment of Elderly Patients with Multiple Myeloma. 2018 , 61-71		1
110	Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. 2018 , 7, 307-316		21
109	Upfront treatment of elderly myeloma patients: an overview and update. <i>Expert Review of Hematology</i> , 2018 , 11, 99-108	2.8	3

108	Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression. 2018 , 16, 1138-1148		24
107	Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma. 2018 , 18, 210-218		15
106	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. <i>Blood Cancer Journal</i> , 2018 , 8, 26	7	68
105	Two States of Myeloma Stem Cells. 2018 , 18, 38-43		10
104	Minimal residual disease analysis in myeloma - when, why and where. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1772-1784	1.9	14
103	CAR T cell therapy for multiple myeloma: where are we now and where are we headed?. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2056-2067	1.9	41
102	Drug response prediction in high-risk multiple myeloma. 2018 , 644, 80-86		10
101	Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma. <i>Haematologica</i> , 2018 , 103, 325-335	6.6	17
100	Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity. 2018 , 1100, 141-159		6
99	Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. 2018 , 18, 1152		9
98	Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. <i>Blood Cancer Journal</i> , 2018 , 8, 123	7	47
97	The power of proteasome inhibition in multiple myeloma. 2018 , 15, 1033-1052		25
96	PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. 2018 , 10, 121		20
95	Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma. 2018 , 80, 288-295		29
94	A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. <i>Blood Advances</i> , 2018 , 2, 2400-2411	7.8	3
93	Bloodless tandem autologous transplant in Jehovah's Witness patients. 2018 , 53, 1428-1433		3
92	Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. 2018 , 182, 231-244		23
91	Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic. <i>Expert Review of Hematology</i> , 2018 , 11, 513-523	2.8	7

90	Potential of oncolytic viruses in the treatment of multiple myeloma. 2017 , 7, 1-12		9
89	Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. <i>Leukemia</i> , 2019 , 33, 457-468	10.7	51
88	High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. 2019 , 8,		29
87	Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. 2019 , 186, 807-819		6
86	Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. 2019 , 12, 65		4
85	Relapsed refractory multiple myeloma: a comprehensive overview. <i>Leukemia</i> , 2019 , 33, 2343-2357	10.7	50
84	Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. 2019 , 103, 107-115		12
83	Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. 2019 , 28, 421-433		5
82	[Impact of minimal residual disease detection after treatment of multiple myeloma]. 2019 , 160, 502-508		
81	The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. 2019 , 20,		35
80	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. 2019 , 19, 332-344		13
79	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. <i>Haematologica</i> , 2019 , 104, 1440-1450	6.6	39
78	Myeloma sleeper agent in myeloid disguise. <i>Blood</i> , 2019 , 134, 3-4	2.2	5
77	Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 2-10	2.2	6
76	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019 , 3, e300	0.3	11
75	Recurrent Infections in a Patient with Multiple Myeloma. <i>Journal of Health and Allied Sciences NU</i> , 2019 , 09, 81-84	0.2	
74	[CD38 antibodies in multiple myeloma]. <i>Medecine/Sciences</i> , 2019 , 35, 1001-1004		0
73	Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma. <i>EBioMedicine</i> , 2019 , 39, 612-620	8.8	12

72	Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019 , 392, 461-466	3.4	
71	Molecular signatures of multiple myeloma progression through single cell RNA-Seq. <i>Blood Cancer Journal</i> , 2019 , 9, 2	7	37
70	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019 , 33, 730-738	10.7	11
69	[Pathogenesis of multiple myeloma]. <i>Der Internist</i> , 2019 , 60, 3-9	0	1
68	Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. <i>Leukemia</i> , 2019 , 33, 766-771	10.7	44
67	Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives. <i>Briefings in Bioinformatics</i> , 2020 , 21, 936-945	13.4	12
66	Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. <i>European Journal of Health Economics</i> , 2020 , 21, 219-233	3.6	2
65	Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease. <i>Cytometry Part B - Clinical Cytometry</i> , 2020 , 98, 161-173	3.4	15
64	A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 476, 337-351	5.1	14
63	Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective Deutsche Studiengruppe MMP(DSM) and European Myeloma Network(EMN) analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 875-886	1.9	5
62	EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma. <i>Oncologist</i> , 2020 , 25, 1067-1074	5.7	1
61	An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2020 , 13, 795-802	2.8	1
60	Social frailty predicts worse outcomes in patients with multiple myeloma: A novelty in an old approach. <i>EJHaem</i> , 2020 , 1, 103-112	0.9	1
59	The Acidic Microenvironment: Is It a Phenotype of All Cancers? A Focus on Multiple Myeloma and Some Analogies with Diabetes Mellitus. <i>Cancers</i> , 2020 , 12,	6.6	8
58	Daratumumab subcutaneous formulation for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1253-1259	5.4	1
57	Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 87	7	7
56	Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. <i>Annals of Hematology</i> , 2020 , 99, 1257-1264	3	5
55	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. <i>Nature Communications</i> , 2020 , 11, 1228	17.4	24

54	Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins. <i>Clinical Chemistry</i> , 2020 , 66, 421-433	5.5	20
53	Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. <i>International Journal of Hematology</i> , 2020 , 111, 512-518	2.3	4
52	B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. <i>Leukemia</i> , 2020 , 34, 985-1005	10.7	114
51	Antibody therapies for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 295-303	5.4	5
50	Long-term outcomes after autologous stem cell transplantation for multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 422-431	7.8	30
49	MK2 is a therapeutic target for high-risk multiple myeloma. <i>Haematologica</i> , 2021 , 106, 1774-1777	6.6	5
48	Approaching the first relapse after autologous transplant in multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , 2021 , 4,	1.2	
47	Autonomic nervous system control of multiple myeloma. <i>Blood Reviews</i> , 2021 , 46, 100741	11.1	4
46	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. <i>Blood</i> , 2021 , 137, 49-60	2.2	28
45	Cell-Membrane-Display Nanotechnology. <i>Advanced Healthcare Materials</i> , 2021 , 10, e2001014	10.1	5
44	Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. <i>Onc Immunology</i> , 2021 , 10, 1859263	7.2	3
43	Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma. <i>Exploration of Targeted Anti-tumor Therapy</i> ,	2.5	
42	Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma. <i>Exploration of Targeted Anti-tumor Therapy</i> ,	2.5	
41	Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021 , 12, 632937	8.4	8
40	A Qualitative Study of the Experiences of Living With Multiple Myeloma. <i>Oncology Nursing Forum</i> , 2021 , 48, 151-160	1.7	2
39	Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021 , 12, 667054	8.4	
38	TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	1
37	Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria. <i>Scientific Reports</i> , 2021 , 11, 14956	4.9	0

36	Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift. <i>JCO Oncology Practice</i> , 2021 , 17, 405-413	2.3	5
35	Requirements for operational cure in multiple myeloma. <i>Blood</i> , 2021 , 138, 1406-1411	2.2	1
34	Does myeloma genetic have an effect on stem cell mobilization?. <i>Transfusion and Apheresis Science</i> , 2021 , 103249	2.4	
33	Single cell RNA-seq data and bulk gene profiles reveal a novel signature of disease progression in multiple myeloma. <i>Cancer Cell International</i> , 2021 , 21, 511	6.4	0
32	In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [F]FDG and [Cu]Cu-LLP2A PET. <i>EJNMMI Research</i> , 2021 , 11, 97	3.6	0
31	What to do with minimal residual disease testing in myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 137-141	3.1	3
30	Recent advances in understanding multiple myeloma. <i>F1000Research</i> , 2016 , 5,	3.6	8
29	Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics. <i>PLoS ONE</i> , 2016 , 11, e0147381	3.7	13
28	Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. <i>PLoS ONE</i> , 2016 , 11, e0166627	3.7	4
27	BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling. <i>Oncotarget</i> , 2017 , 8, 56858-56867	3.3	4
26	Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment. <i>Oncotarget</i> , 2015 , 6, 20621-35	3.3	14
25	Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. <i>Oncotarget</i> , 2016 , 7, 4062-76	3.3	26
24	Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells. <i>Oncotarget</i> , 2016 , 7, 11299-309	3.3	14
23	The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. <i>Oncotarget</i> , 2016 , 7, 48732-48752	3.3	26
22	Minimal residual disease in multiple myeloma: current status. <i>Biomarker Research</i> , 2021 , 9, 75	8	0
21	A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma. <i>International Journal of Clinical Oncology</i> , 2021 , 1	4.2	1
20	Treatment of elderly patients with myeloma. 2015 , 41-63		
19	Stem Cell Transplantation for Multiple Myeloma. <i>Pancreatic Islet Biology</i> , 2017 , 73-86	0.4	

18	Multiple myeloma and differential diagnostic of back pain. <i>Onkologie (Czech Republic)</i> , 2017 , 11, 300-305.	0.1	0
17	Multiple Myeloma and Other Plasma Cell Neoplasms. 2018 , 642-663.	e1	
16	The role of angiogenesis in multiple myeloma treatment. 2020 , 56, 1-6		
15	The effect of novel therapies in high-molecular-risk multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2017 , 15, 870-879	0.6	6
14	Integrating Emerging Data Into Clinical Practice: A Case-Based Approach for Multiple Myeloma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017 , 8, 365-377	0.7	2
13	[Application of 8-color fluorescent antibody panels to detect minimal residual disease in multiple myeloma and its significance]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , 2019 , 40, 156-159.	0.4	
12	Early and late relapses of multiple myeloma after autologous haematopoietic stem cell transplantation. <i>Gematologiya I Transfuziologiya</i> , 2021 , 66, 512-525	0.4	
11	CDK9 inhibitors in multiple myeloma: a review of progress and perspectives.. <i>Medical Oncology</i> , 2022 , 39, 39	3.7	1
10	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.. <i>Blood Cancer Journal</i> , 2022 , 12, 9	7	4
9	Cancer-cell-biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing. <i>Advanced Materials</i> , 2021 , e2107883	24	5
8	Down-regulation of circ_0058058 suppresses proliferation, angiogenesis and metastasis in multiple myeloma through miR-338-3p/ATG14 pathway.. <i>Journal of Orthopaedic Surgery and Research</i> , 2021 , 16, 723	2.8	2
7	Moving Toward a Cure in Multiple Myeloma: Eradication of Measurable Residual Disease. <i>Advances in Oncology</i> , 2022 , 2, 159-169		
6	Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. <i>Transplantation and Cellular Therapy</i> , 2022 ,		
5	Autologe Transplantation (Grundlage und Mechanismen: Hochdosischemotherapie; klinische Anwendungen; Langzeitkomplikationen; MDS und sekundäre Malignome). <i>Springer Reference Medizin</i> , 2022 , 1-8	0	
4	Trial designs and endpoints for immune therapies in multiple myeloma.		1
3	Rebooting the Myeloma Treatment Programme. 36-43		0
2	Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?. 2022 , 23, 15879		0
1	Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. 2023 , 15, 1558		0

